BRPI1008517A2 - direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas. - Google Patents
direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.Info
- Publication number
- BRPI1008517A2 BRPI1008517A2 BRPI1008517A BRPI1008517A BRPI1008517A2 BR PI1008517 A2 BRPI1008517 A2 BR PI1008517A2 BR PI1008517 A BRPI1008517 A BR PI1008517A BR PI1008517 A BRPI1008517 A BR PI1008517A BR PI1008517 A2 BRPI1008517 A2 BR PI1008517A2
- Authority
- BR
- Brazil
- Prior art keywords
- mir
- treatment
- heart disease
- dual targeting
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14991509P | 2009-02-04 | 2009-02-04 | |
| PCT/US2010/023234 WO2010091204A1 (en) | 2009-02-04 | 2010-02-04 | Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1008517A2 true BRPI1008517A2 (pt) | 2016-03-08 |
Family
ID=42542383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008517A BRPI1008517A2 (pt) | 2009-02-04 | 2010-02-04 | direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8629119B2 (pt) |
| EP (1) | EP2393945A4 (pt) |
| JP (1) | JP5943608B2 (pt) |
| KR (1) | KR20110128838A (pt) |
| CN (1) | CN102356162A (pt) |
| AU (1) | AU2010210605B2 (pt) |
| BR (1) | BRPI1008517A2 (pt) |
| CA (1) | CA2751489A1 (pt) |
| MX (1) | MX2011008190A (pt) |
| NZ (1) | NZ594365A (pt) |
| RU (1) | RU2515926C2 (pt) |
| UA (1) | UA105029C2 (pt) |
| WO (1) | WO2010091204A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103492569B (zh) * | 2010-11-05 | 2020-04-07 | 米拉根医疗公司 | 碱基经修饰的寡核苷酸 |
| EP2652151A2 (en) | 2010-12-15 | 2013-10-23 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| AU2011343719A1 (en) * | 2010-12-15 | 2013-04-11 | Miragen Therapeutics | Blood-borne miRNAs as surrogate markers of drug efficacy for cardiac conditions |
| EP2763703B1 (en) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Control of whole body energy homeostasis by microrna regulation |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| CN102980920A (zh) * | 2012-11-14 | 2013-03-20 | 华东师范大学 | 同时检测miRNAs与蛋白标记物的硅纳米线芯片及其检测方法和应用 |
| CN105154445B (zh) * | 2014-06-12 | 2018-07-27 | 中国科学院上海生命科学研究院 | 新的肌营养不良肌病的血清miRNA标志物 |
| WO2016022536A2 (en) * | 2014-08-04 | 2016-02-11 | MiRagen Therapeutics, Inc. | Inhibitors of myh7b and uses thereof |
| HK1249108A1 (zh) | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| MX368314B (es) * | 2015-06-05 | 2019-09-27 | Miragen Therapeutics Inc | Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl). |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN108815535B (zh) * | 2018-08-08 | 2020-05-19 | 哈尔滨医科大学 | 一种抗心肌肌钙蛋白抗体修饰并载有miR-21的脂质体及其制备方法和应用 |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| TW202241459A (zh) * | 2020-12-23 | 2022-11-01 | 南韓商生物歐賽加有限責任公司 | ｍｉＲＮＡ—４８５抑制劑用於誘導毛髮生長之用途 |
| CN117186875B (zh) * | 2023-08-29 | 2026-08-11 | 东南大学 | 一种制备基于分子信标的阳离子脂质体的方法及其产品和应用 |
| CN119246849B (zh) * | 2024-12-09 | 2025-03-14 | 上海基灵生物科技有限公司 | 一种检测犬心脏损伤的试剂盒及应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004522411A (ja) | 2000-07-31 | 2004-07-29 | ジーン ロジック インコーポレイテッド | 分子毒性学モデリング |
| AU2001286221B2 (en) * | 2000-09-13 | 2006-09-28 | Chugai Seiyaku Kabushiki Kaisha | Remedies for ischemic diseases |
| CZ20031569A3 (cs) * | 2000-12-07 | 2003-11-12 | Gencell S. A. | Polynukleotidy obsahující fragment sekvence v protisměru od genu CARP, vektory a expresní kazety, které je obsahují, a jejich použití |
| US20050124568A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
| US6964950B2 (en) * | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| JP2006502693A (ja) | 2002-02-04 | 2006-01-26 | ジーン ロジック インコーポレイテッド | 初代ラット肝細胞毒性モデリング |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005078096A2 (en) | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| CA2556435C (en) | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
| EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| WO2006013561A2 (en) | 2004-08-02 | 2006-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for diagnosing and treating post traumatic stress disorder |
| JP2006101790A (ja) | 2004-10-06 | 2006-04-20 | Japan Health Science Foundation | 高血圧症のリスクの評価方法 |
| US20080269072A1 (en) | 2004-10-21 | 2008-10-30 | Hart Ronald P | Rational Probe Optimization for Detection of MicroRNAs |
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US9550990B2 (en) | 2004-12-10 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| EP1874936B1 (en) | 2005-04-19 | 2013-10-30 | BASF Plant Science GmbH | Improved methods controlling gene expression |
| DK2002003T3 (en) | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
| WO2007035684A2 (en) | 2005-09-16 | 2007-03-29 | Primera Biosystems, Inc. | Method for quantitative detection of short rna molecules |
| US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| CA2634046A1 (en) | 2005-12-12 | 2007-06-21 | The University Of North Carolina At Chapel Hill | Micrornas that regulate muscle cell proliferation and differentiation |
| US20100286044A1 (en) | 2005-12-29 | 2010-11-11 | Exiqon A/S | Detection of tissue origin of cancer |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| DK2056882T3 (da) * | 2006-08-01 | 2012-11-19 | Univ Texas | Identifikation af en mikro-rna, som aktiverer ekspression af en tung kæde med beta-myosin |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| BRPI0719995A2 (pt) | 2006-12-14 | 2014-03-18 | Novartis Ag | Composições e métodos para tratar distúrbios musculares & cardiovasculares |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| CA2694928A1 (en) * | 2007-07-31 | 2009-02-05 | Board Of Regents, The University Of Texas System | Micro-rnas that control myosin expression and myofiber identity |
| WO2009026574A2 (en) | 2007-08-23 | 2009-02-26 | Keren Pharmaceutical, Inc. | Immunogenic compositions and uses thereof |
| DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| WO2009062169A2 (en) | 2007-11-09 | 2009-05-14 | The Board Of Regents Of The University Of Texas System | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
| US20110160285A1 (en) | 2008-03-13 | 2011-06-30 | The Regents Of The University Of Colorado | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| CA2726052A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| US8193161B2 (en) | 2008-06-09 | 2012-06-05 | New York Medical College | Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
-
2010
- 2010-02-04 US US13/147,784 patent/US8629119B2/en not_active Expired - Fee Related
- 2010-02-04 KR KR20117020396A patent/KR20110128838A/ko not_active Ceased
- 2010-02-04 RU RU2011136640/10A patent/RU2515926C2/ru not_active IP Right Cessation
- 2010-02-04 MX MX2011008190A patent/MX2011008190A/es active IP Right Grant
- 2010-02-04 WO PCT/US2010/023234 patent/WO2010091204A1/en not_active Ceased
- 2010-02-04 EP EP20100739137 patent/EP2393945A4/en not_active Withdrawn
- 2010-02-04 BR BRPI1008517A patent/BRPI1008517A2/pt not_active IP Right Cessation
- 2010-02-04 UA UAA201110646A patent/UA105029C2/uk unknown
- 2010-02-04 JP JP2011548431A patent/JP5943608B2/ja not_active Expired - Fee Related
- 2010-02-04 NZ NZ59436510A patent/NZ594365A/xx not_active IP Right Cessation
- 2010-02-04 CA CA 2751489 patent/CA2751489A1/en not_active Abandoned
- 2010-02-04 CN CN2010800123730A patent/CN102356162A/zh active Pending
- 2010-02-04 AU AU2010210605A patent/AU2010210605B2/en not_active Ceased
-
2013
- 2013-12-12 US US14/104,886 patent/US20140179764A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2751489A1 (en) | 2010-08-12 |
| AU2010210605A1 (en) | 2011-08-25 |
| RU2011136640A (ru) | 2013-03-10 |
| JP5943608B2 (ja) | 2016-07-05 |
| MX2011008190A (es) | 2011-10-06 |
| CN102356162A (zh) | 2012-02-15 |
| EP2393945A4 (en) | 2013-08-07 |
| JP2012516856A (ja) | 2012-07-26 |
| US8629119B2 (en) | 2014-01-14 |
| WO2010091204A1 (en) | 2010-08-12 |
| AU2010210605B2 (en) | 2015-08-13 |
| UA105029C2 (uk) | 2014-04-10 |
| KR20110128838A (ko) | 2011-11-30 |
| EP2393945A1 (en) | 2011-12-14 |
| RU2515926C2 (ru) | 2014-05-20 |
| US20140179764A1 (en) | 2014-06-26 |
| NZ594365A (en) | 2013-03-28 |
| US20120035243A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20240036I1 (fi) | Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L | |
| IL253891A0 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| BR112012002124A2 (pt) | tratamento da doença de crohn com laquinimode. | |
| PL2442814T3 (pl) | Bifidobacteria do leczenia cukrzycy i pokrewnych chorób | |
| EP2327448A4 (en) | defibrillation catheter | |
| IL258794B (en) | Methods and compositions for diagnosis and treatment of cancer | |
| PL2376537T3 (pl) | Ludzkie przeciwciała przeciwko ludzkiemu czynnikowi tkankowemu | |
| BRPI1009220A2 (pt) | "tratamento ultrasônico de tecido adiposo em múltiplas profundidades." | |
| BRPI1016199A2 (pt) | cobertura de ferimento e kit de tratamento de ferimentos. | |
| BRPI0917567A2 (pt) | tratamento de doença respiratória | |
| IL217540A (en) | Oral composition for use in oral disinfection or in treating an oral disease | |
| BRPI1006244A2 (pt) | sistema de cateter de desfibrilação intracardiaca | |
| IT1391555B1 (it) | Apparato trattamento extracorporeo sangue | |
| BR112013013684A2 (pt) | tratamento das condiçóes mediadas por jak-2 | |
| BRPI0815551A2 (pt) | Tratamento através de hucbc de doença beta-amiloide | |
| EP2393945A4 (en) | DOUBLE TARGETING ON MIR-208 AND MIR-499 IN THE TREATMENT OF HEART DISEASES | |
| ME03508B (me) | Kombinovana terapija za liječenje dijabetesa | |
| BR112012008063A2 (pt) | galectina-3 e terapia de ressincronização cardíaca. | |
| EP2799540A4 (en) | HUMAN ARGINASE AND PEGYLATED HUMAN ARGINASE AND USE THEREOF | |
| GB0922085D0 (en) | Cancer diagnosis and treatment | |
| BRPI0813364A2 (pt) | Métodos de diagnóstico e tratamento de câncer. | |
| BR112012003844A2 (pt) | vacinas de pttv e diagnóstico | |
| IL240560A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| PL2430452T3 (pl) | Diagnoza i leczenie raka w oparciu o genotyp odc1 | |
| BR112014009789A2 (pt) | cisteamina no tratamento da doença fibrótica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |